Torri A, Beretta O, Ranghetti A, et al. Gene expression profiles identify inflammatory signatures in
dendritic cells. PLoS One. 2010. doi:10.1371/journal.pone.0009404.
Walker MS, Hughes TA. Messenger RNA expression profiling using DNA microarray technology: diagnostic tool,
scientific analysis or un-interpretable data? (review). Int J Mol Med. 2008;21(1):13-17.
Linsley PS, Chaussabel D, Speake C. The relationship of immune cell signatures to patient survival varies
within and between tumor types. PLoS One. 2015. doi:10.1371/journal.pone.0138726.
Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic,
predictive, and mechanistic signatures. Immunity. 2013;39(1):11-26.
Cesano A, Warren S. Bringing the next generation of immune-oncology biomarkers to the clinic. Biomedicines.
2018. doi:10.3390/biomedicines6010014.
Ikeda H, Old LJ, Schreiber RD. The roles of IFNγ in protection against tumor development and cancer
immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95-109.
Abiko K, Matsumura N, Hamanishi J, et al. IFN-γ from lymphocytes induces PD-L1 expression and promotes
progression of ovarian cancer. Br J Cancer. 2015;112(9):1501-1509.
Fumagalli D, Blanchet-Cohen A, Brown D, et al. Transfer of clinically relevant gene expression signatures
in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology. BMC Genomics. 2014.
doi:10.1186/1471-2164-15-1008.
Finotello F, Di Camillo B. Measuring differential gene expression with RNA-seq: challenges and strategies
for data analysis. Brief Funct Genomics. 2015;14(2):130-142. 12.Sharma P, Retz M, Siefker-Radtke A, et al.
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre,
single-arm, phase 2 trial. Lancet Oncology. 2017;18(3):312-322.